Complement-targeted therapy for autoimmune diseases
The success and safety seen in treating complement-mediated hemolysis conditions has sparked the development of targeted therapies for rare autoimmune diseases, with expansion to more common autoimmune conditions. Various classes of drugs, including small molecules, peptides, monoclonal antibodies,...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
De Gruyter
2023-12-01
|
| Series: | Medical Review |
| Subjects: | |
| Online Access: | https://doi.org/10.1515/mr-2023-0051 |
| _version_ | 1797340949115830272 |
|---|---|
| author | Chu Cong-Qiu |
| author_facet | Chu Cong-Qiu |
| author_sort | Chu Cong-Qiu |
| collection | DOAJ |
| description | The success and safety seen in treating complement-mediated hemolysis conditions has sparked the development of targeted therapies for rare autoimmune diseases, with expansion to more common autoimmune conditions. Various classes of drugs, including small molecules, peptides, monoclonal antibodies, and small interfering RNA (siRNA), are undergoing development to specifically address complement activity. A dual approach targeting both complement and other immune components may be required for autoimmune diseases characterized by inflammation and complex pathogenic mechanisms. siRNA, which suppresses complement production, is emerging as a potent therapeutic tool. Combining a complement-blocking siRNA drug with a treatment that reduces autoantibodies could prove clinically feasible and impactful in managing these conditions. |
| first_indexed | 2024-03-08T10:10:50Z |
| format | Article |
| id | doaj.art-7321629956774e9c95097409ba06661d |
| institution | Directory Open Access Journal |
| issn | 2749-9642 |
| language | English |
| last_indexed | 2024-03-08T10:10:50Z |
| publishDate | 2023-12-01 |
| publisher | De Gruyter |
| record_format | Article |
| series | Medical Review |
| spelling | doaj.art-7321629956774e9c95097409ba06661d2024-01-29T08:48:35ZengDe GruyterMedical Review2749-96422023-12-013652152510.1515/mr-2023-0051Complement-targeted therapy for autoimmune diseasesChu Cong-Qiu0Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, OR, USAThe success and safety seen in treating complement-mediated hemolysis conditions has sparked the development of targeted therapies for rare autoimmune diseases, with expansion to more common autoimmune conditions. Various classes of drugs, including small molecules, peptides, monoclonal antibodies, and small interfering RNA (siRNA), are undergoing development to specifically address complement activity. A dual approach targeting both complement and other immune components may be required for autoimmune diseases characterized by inflammation and complex pathogenic mechanisms. siRNA, which suppresses complement production, is emerging as a potent therapeutic tool. Combining a complement-blocking siRNA drug with a treatment that reduces autoantibodies could prove clinically feasible and impactful in managing these conditions.https://doi.org/10.1515/mr-2023-0051complementautoimmune diseasessirnadual target |
| spellingShingle | Chu Cong-Qiu Complement-targeted therapy for autoimmune diseases Medical Review complement autoimmune diseases sirna dual target |
| title | Complement-targeted therapy for autoimmune diseases |
| title_full | Complement-targeted therapy for autoimmune diseases |
| title_fullStr | Complement-targeted therapy for autoimmune diseases |
| title_full_unstemmed | Complement-targeted therapy for autoimmune diseases |
| title_short | Complement-targeted therapy for autoimmune diseases |
| title_sort | complement targeted therapy for autoimmune diseases |
| topic | complement autoimmune diseases sirna dual target |
| url | https://doi.org/10.1515/mr-2023-0051 |
| work_keys_str_mv | AT chucongqiu complementtargetedtherapyforautoimmunediseases |